Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

Sponsor
University of Pittsburgh
Study ID
NCT02593929
Phase
EARLY_PHASE1
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will identify baseline and/or pharmacodynamic biomarkers of response to ruxolitinib, based upon association with quantitative change in tumor size following 14-21 days of neoadjuvant ruxolitinib in patients with operable HNSCC.

Key Dates

First listed
Nov 2, 2015
Start date
Jan 31, 2017
Status verified
Jan 2017
Primary completion
Jan 31, 2018

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ruxolitinib
    Ruxolitinib will be taken orally for 14-21 days prior to surgery, every morning and every evening, and will be discontinued after the morning dose on the day of planned surgical resection.

Primary Outcome Measure

baseline and/or pharmacodynamic biomarkers of response to ruxolitinib based upon association with change in tumor size [ Time Frame: 14-21 days ]

Find similar trials

Nationwide
Head and neck cancer trialsOncology trialsENT trials

Related Studies